A Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping to Evaluate the Safety and Efficacy of ENTR-601-45
Conditions
Duchenne Muscular Dystrophy (DMD)
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
University Hospital Gent, Ghent, Belgium
Contact: Principal Investigator (Nicolas Deconinck)UZ Leuven, Leuven, Belgium
Contact: Principal Investigator (Liesbeth De Waele)Centre Hospitalier Régional de la Citadelle, Liège, Belgium
Contact: Principal Investigator (Aurore Daron)IRCCS Ospedale San Raffaele, Milan, Italy
Contact: Principal Investigator (Stefano Previtali)Ospedale Pediatrico Bambino Gesu, Rome, Italy
Contact: Principal Investigator (Adele D'Amico)Fondazione Policlinico Universitario A. Gemelli IRCCS - Universita Cattolica del Sacro Cuore, Rome, Italy
Contact: Study coordinator (Eugenio Maria Mercuri) · eugeniomaria.mercuri@policlinicogemelli.it · 06 3015 4860Contact: Principal Investigator (Eugenio Maria Mercuri)Leids Universitair Medisch Centrum, Leiden, Netherlands
Contact: Principal Investigator (Erik Niks)Stichting Radboud Universitair Medisch Centrum, Nijmegen, Netherlands
Contact: Principal Investigator (Saskia Houwen)Hospital Universitario Vall d'Hebron, Barcelona, Spain
Contact: Principal Investigator (David Gomez Andres)Hospital Sant Joan de Deu, Barcelona, Spain
Contact: Principal Investigator (Andres Nascimento)Leeds General Infirmary, Leeds, United Kingdom
Contact: Principal Investigator (Cristina Martos Lozano)Alder Hey Children's NHS Foundation Trust, Liverpool, United Kingdom
Contact: Principal Investigator (Rajesh Madhu)Great Ormond Street Hospital for Children, London, United Kingdom
Contact: Principal Investigator (Giovanni Baranello)Royal Manchester Children's Hospital, Manchester, United Kingdom
Contact: Principal Investigator (Gary McCullagh)Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom
Contact: Principal Investigator (Laurent Servais)
Study leads
Entrada Therapeutics Clinical Trials
Study Director
Entrada Therapeutics, Inc.